William Blair Investment Management LLC Increases Holdings in Quanterix Corporation $QTRX

William Blair Investment Management LLC increased its stake in shares of Quanterix Corporation (NASDAQ:QTRX) by 16.6% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 1,315,280 shares of the company’s stock after purchasing an additional 187,299 shares during the period. William Blair Investment Management LLC owned 2.83% of Quanterix worth $7,142,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. R Squared Ltd bought a new stake in shares of Quanterix during the third quarter valued at about $64,000. HUB Investment Partners LLC purchased a new position in Quanterix during the second quarter valued at approximately $81,000. Brevan Howard Capital Management LP purchased a new position in Quanterix during the second quarter valued at approximately $96,000. State of Wyoming increased its holdings in Quanterix by 105.3% during the 2nd quarter. State of Wyoming now owns 14,814 shares of the company’s stock worth $99,000 after acquiring an additional 7,599 shares during the period. Finally, Intech Investment Management LLC lifted its stake in Quanterix by 13.4% in the 3rd quarter. Intech Investment Management LLC now owns 19,161 shares of the company’s stock worth $104,000 after purchasing an additional 2,268 shares in the last quarter. Institutional investors own 86.48% of the company’s stock.

Quanterix Trading Down 7.3%

QTRX opened at $5.87 on Wednesday. The stock has a market capitalization of $274.19 million, a P/E ratio of -2.33 and a beta of 1.05. The stock has a 50-day moving average price of $6.49 and a 200-day moving average price of $6.01. Quanterix Corporation has a 12-month low of $4.05 and a 12-month high of $8.77.

Quanterix (NASDAQ:QTRX) last released its earnings results on Monday, March 2nd. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.11). The firm had revenue of $41.40 million during the quarter, compared to the consensus estimate of $37.95 million. Quanterix had a negative return on equity of 23.72% and a negative net margin of 77.14%. On average, equities research analysts predict that Quanterix Corporation will post -0.98 EPS for the current year.

Wall Street Analyst Weigh In

QTRX has been the subject of a number of recent analyst reports. Canaccord Genuity Group boosted their price target on shares of Quanterix from $5.00 to $8.00 and gave the company a “hold” rating in a research report on Monday, December 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Quanterix in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised Quanterix from a “sell” rating to a “hold” rating in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $11.33.

Quanterix Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.